Culture
Teamwork. Excellence. Creativity. Entrepreneurial spirit. At PsychoGenics, we love what we do. We care deeply about making a meaningful difference...
Preclinical Neurodegenerative Disorders Research
PsychoGenics has established itself as a reputable partner in preclinical research for neurodegenerative disorders. Our depth of expertise in preclinical...
Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer’s Disease
Gelman S, Palma J, Tombaugh G, Ghavami A Journal of Alzheimer’s Disease, vol. 61, no. 1, pp. 195-208, 2018 DOI:...
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc....
Emyria teams with CRO PsychoGenics for MDMA-like Drug Development
By Joseph Keenan · Sep 21, 2022 · Fierce Biotech Australian biotech Emyria and U.S.-based CRO PsychoGenics have agreed to a collaborate on...
Emyria Starts Program with Neuroscience Drug Discovery CRO
By Jim Cornall · Sept 22, 2022 · Labiotech.eu Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics,...
PsychoGenics Highlights a Long-term Collaboration with the TSC Alliance on Rare Disease Day
Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC...
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997 is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using PsychoGenics’ AI-enabled phenotypic screening platforms. PsychoGenics intends to evaluate RO7117997 as a potential treatment for several psychiatric and neurological conditions, starting with sleep and seizure disorders.
Cell & Gene Therapy Development
PsychoGenics’ entire catalog of services can be applied to the preclinical testing of your cell and gene therapy (CGT) product...
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods.
Houghten, R. A.; Pinilla, C.; Giulianotti, M. A.; Appel, J. R.; Dooley, C. T.; Nefzi, A.; Ostresh, J. M.; Yu,...